{"id":8319,"date":"2022-07-14T12:09:30","date_gmt":"2022-07-14T12:09:30","guid":{"rendered":"https:\/\/marylanddailygazette.com\/ulcerative-colitis-market-size-2022-2027-industry-share-global-trends-top-companies-overview-demand-and-forecast\/"},"modified":"2022-07-14T12:09:30","modified_gmt":"2022-07-14T12:09:30","slug":"ulcerative-colitis-market-size-2022-2027-industry-share-global-trends-top-companies-overview-demand-and-forecast","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/ulcerative-colitis-market-size-2022-2027-industry-share-global-trends-top-companies-overview-demand-and-forecast\/","title":{"rendered":"Ulcerative Colitis Market Size 2022-2027, Industry Share, Global Trends, Top Companies Overview, Demand and Forecast"},"content":{"rendered":"

Ulcerative Colitis Market Size 2022-2027, Industry Share, Global Trends, Top Companies Overview, Demand and Forecast<\/a><\/p>\n

The latest research study \u201cUlcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027<\/b>\u201d by IMARC Group, finds that the global ulcerative colitis market reached a value<\/a> of US$ 6.92 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.71 Billion by 2027, exhibiting a CAGR of 5.60% during 2022-2027.<\/div>\n

Covid-19 Impact: <\/b><\/p>\n

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.<\/p>\n

Industry Definition and Application:<\/b><\/p>\n

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that causes inflammation, irritation, and ulcers (sores) in the digestive tract. It specifically affects the inner lining of the large intestine (or colon) and rectum. The symptoms of this disease develop gradually, and individuals diagnosed with UC observe periods with mild or no symptoms, although it can sometimes lead to life-threatening or debilitating complications. There is no cure for UC yet; however, the treatment can assist the patients in minimizing and managing their symptoms, bringing about long-term remission, and preventing flare-ups. Consequently, UC treatment is widely gaining traction worldwide as it improves the quality of life and ensures the mental and physical well-being of the patients.<\/p>\n

\"Ulcerative<\/a><\/div>\n

Global Ulcerative Colitis Market Trends and Drivers: <\/b><\/p>\n

One of the primary factors driving the market is the increasing number of patients diagnosed with UC and the rising awareness about the treatment options available. Additionally, governments of various nations are taking several initiatives to spread awareness about ulcerative colitis and improve the availability and accessibility of healthcare facilities. Furthermore, the extensive investments in the research and development (R&D) activities for introducing novel therapists are creating a positive market outlook. In line with this, several leading players are introducing more effective and innovative drugs to increase their product portfolio. Other growth-inducing factors are improving healthcare infrastructure, growing disposable incomes, favorable reimbursement policies, and the easy availability of biosimilar drugs.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Ulcerative Colitis Market <\/span><\/b>Report Scope<\/b><\/o:p><\/p>\n<\/td>\n<\/tr>\n

\n

Report Coverage<\/b><\/o:p><\/p>\n<\/td>\n

\n

Details<\/b><\/o:p><\/p>\n<\/td>\n<\/tr>\n

\n

Market size value in 2021<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

US$ 6.92 Billion<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Market forecast in 2027<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

US$ 9.71 Billion<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Growth Rate<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

CAGR of 5.60% from 2022 to 2027<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Base year for estimation<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

2021<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Historical data<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

2016-2021<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Forecast period<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

2022-2027<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Report coverage<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

Revenue forecast, company ranking, competitive landscape, growth factors, and trends<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Segments covered<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel and Region<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Regional scope<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Key companies profiled<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Market Dynamics<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Customization preview<\/span><\/o:p><\/span><\/p>\n<\/td>\n

\n

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.<\/span><\/o:p><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Report Segmentation: 
<\/b><\/p>\n

The report has been segmented the market into following categories:\n<\/p>\n

Breakup by Type:<\/b><\/p>\n

\u2022 <\/span>Mild UC<\/p>\n

\u2022 <\/span>Moderate UC<\/p>\n

\u2022 <\/span>Severe UC\n<\/p>\n

Breakup by Disease Type:<\/b><\/p>\n

\u2022 <\/span>Ulcerative Proctitis<\/p>\n

\u2022 <\/span>Proctosigmoiditis<\/p>\n

\u2022 <\/span>Left-sided Colitis<\/p>\n

\u2022 <\/span>Pancolitis or Universal Colitis<\/p>\n

\u2022 <\/span>Fulminant Colitis\n<\/p>\n

Breakup by Molecule Type:<\/b><\/p>\n

\u2022 <\/span>Small Molecules<\/p>\n

\u2022 <\/span>Biologics\n<\/p>\n

Breakup by Drug Type:<\/b><\/p>\n

\u2022 <\/span>Anti-Inflammatory Drugs<\/p>\n

\u2022 <\/span>Anti-TNF Biologics<\/p>\n

\u2022 <\/span>Immunosuppressant<\/p>\n

\u2022 <\/span>Calcineurin Inhibitors<\/p>\n

\u2022 <\/span>Others\n<\/p>\n

Breakup by Route of Administration:<\/b><\/p>\n

\u2022 <\/span>Oral<\/p>\n

\u2022 <\/span>Injectable\n<\/p>\n

Breakup by Distribution Channel:<\/b><\/p>\n

\u2022 <\/span>Hospital Pharmacies<\/p>\n

\u2022 <\/span>Retail Pharmacies<\/p>\n

\u2022 <\/span>Drug Store<\/p>\n

\u2022 <\/span>Others\n<\/p>\n

By Geography:
\n<\/b><\/div>\n

\u2022 <\/span>North America<\/b><\/p>\n

o <\/span>United States<\/p>\n

o <\/span>Canada\n<\/p>\n

\u2022 <\/span>Asia-Pacific<\/b><\/p>\n

o <\/span>China<\/p>\n

o <\/span>Japan<\/p>\n

o <\/span>India<\/p>\n

o <\/span>South Korea<\/p>\n

o <\/span>Australia<\/p>\n

o <\/span>Indonesia<\/p>\n

o <\/span>Others\n<\/p>\n

\u2022 <\/span>Europe<\/b><\/p>\n

o <\/span>Germany<\/p>\n

o <\/span>France<\/p>\n

o <\/span>United Kingdom<\/p>\n

o <\/span>Italy<\/p>\n

o <\/span>Spain<\/p>\n

o <\/span>Russia<\/p>\n

o <\/span>Others\n<\/p>\n

\u2022 <\/span>Latin America<\/b><\/p>\n

o <\/span>Brazil<\/p>\n

o <\/span>Mexico<\/p>\n

o <\/span>Others\n<\/p>\n

\u2022 <\/span>Middle East and Africa
\n<\/b><\/div>\n

List of Major Key Players:<\/b><\/p>\n

The major players in the market are Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.<\/p>\n

\n

Explore Latest Market Research Reports by IMARC Group:<\/b><\/p>\n<\/div>\n

About Us:<\/b><\/p>\n

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.<\/p>\n

IMARC\u2019s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company\u2019s expertise.<\/p>\n

Contact Us:<\/b><\/p>\n

IMARC Services Private Limited.<\/p>\n

30 N Gould St Ste R<\/p>\n

Sheridan, WY 82801 USA \u2013 Wyoming<\/p>\n

Tel No:(D) +91 120 433 0800<\/p>\n

Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800<\/p>\n

Published Thu, 14 Jul 2022 07:07:38 -0500<\/p>\n","protected":false},"excerpt":{"rendered":"

Ulcerative Colitis Market Size 2022-2027, Industry Share, Global Trends, Top Companies Overview, Demand and Forecast The latest research study \u201cUlcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027\u201d by IMARC Group, finds that the global ulcerative colitis market reached a value of US$ 6.92 Billion in 2021. Looking forward, IMARC Group expects […]<\/p>\n","protected":false},"author":3,"featured_media":8318,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/8319"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=8319"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/8319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/8318"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=8319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=8319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=8319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}